NCT06352073View on ClinicalTrials.gov

Dupilumab for Eosinophilic Esophagitis With Severe Strictures

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 16, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

August 31, 2026

Conditions
Eosinophilic EsophagitisEoE
Interventions
DRUG

Dupilumab

300mg weekly subcutaneous injection

Trial Locations (1)

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER